S‐1 plus nab‐paclitaxel is a promising regimen for pancreatic cancer in a preclinical model

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Surgical Oncology

• Publication date

  2016-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/jso.24147PMID 27100026
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ormeloxifene suppresses desmoplasia and enhances sensitivity of gemcitabine in pancreatic cancer.

  2015cited by this paper
• Stromal biology and therapy in pancreatic cancer: a changing paradigm

  2015cited by this paper
• Pattern of first recurrent lesions in pancreatic cancer: hepatic relapse is associated with dismal prognosis and portal vein invasion.

  2014cited by this paper
• Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma.

  2014cited by this paper
• Chemotherapeutic Strategies in Advanced or Metastatic Pancreatic Adenocarcinoma

  2014cited by this paper
• p21-Activated Kinase 4 (PAK4) as a Predictive Marker of Gemcitabine Sensitivity in Pancreatic Cancer Cell Lines

  2014cited by this paper
• Stromal disrupting effects of nab-paclitaxel in pancreatic cancer

  2013cited by this paper
• Extended Lymphadenectomy in Pancreatic Cancer Is Crucial

  2013cited by this paper
• Value of peritoneal cytology in potentially resectable pancreatic cancer

  2013cited by this paper
• nab-Paclitaxel mechanisms of action and delivery.

  2013cited by this paper
• SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice

  2013cited by this paper
• Pancreatic cancer.

  2013cited by this paper
• Aggressive Surgery for Borderline Resectable Pancreatic Cancer: Evaluation of National Comprehensive Cancer Network Guidelines

  2013influential reference
• Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer (JASPAC-01 study).

  2013cited by this paper
• Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

  2013cited by this paper
• Therapeutic enhancement of S-1 with CPT-11 through down-regulation of thymidylate synthase in bladder cancer

  2013cited by this paper
• Epithelial-to-mesenchymal transition predicts prognosis of pancreatic cancer.

  2013cited by this paper
• Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.

  2013influential reference
• Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer.

  2013cited by this paper
• Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer

  2012cited by this paper
• S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.

  2012cited by this paper
• nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer.

  2012cited by this paper
• Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.

  2011cited by this paper
• FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

  2011cited by this paper
• Pancreatic cancer

  2011cited by this paper
• Stromal biology and therapy in pancreatic cancer

  2010cited by this paper
• Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (Review).

  2010cited by this paper
• Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study.

  2010cited by this paper
• Second-line therapy for advanced pancreatic cancer: a review of the literature and future directions.

  2009cited by this paper
• Epidemiology of pancreatic cancer: an overview

  2009cited by this paper
• Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer

  2009cited by this paper
• Evolutionary-new centromeres preferentially emerge within gene deserts

  2008cited by this paper
• Phase II Study of a Combination of S-1 and Paclitaxel in Patients with Unresectable or Metastatic Gastric Cancer

  2008cited by this paper
• A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer

  2008cited by this paper
• Changes of gene expression of thymidine phosphorylase, thymidylate synthase, dihydropyrimidine dehydrogenase after the administration of 5'-deoxy-5-fluorouridine, paclitaxel and its combination in human gastric cancer xenografts.

  2008cited by this paper
• S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.

  2008cited by this paper
• Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.

  2007cited by this paper
• Clinical Implications of Peritoneal Cytology in Potentially Resectable Pancreatic Cancer: Positive Peritoneal Cytology May Not Confer an Adverse Prognosis

  2007cited by this paper
• Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

  2007cited by this paper
• Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.

  2006cited by this paper
• Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies

  2006cited by this paper
• Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.

  2005cited by this paper
• The Absence of Human Equilibrative Nucleoside Transporter 1 Is Associated with Reduced Survival in Patients With Gemcitabine-Treated Pancreas Adenocarcinoma

  2004cited by this paper
• Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.

  2002cited by this paper
• Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells.

  2002cited by this paper
• Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel.

  2001cited by this paper
• Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth.

  2000cited by this paper
• Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines.

  1998cited by this paper
• Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

  1997cited by this paper
• Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators.

  1996cited by this paper
• Promotion of microtubule assembly in vitro by taxol

  1979cited by this paper

• Noninvasive Computed Tomography-Based Quantification of Tumor Fibrosis Predicts Pancreatic Cancer Response to Gemcitabine/Nab-Paclitaxel

  2025cites this paper
• Combined Chemotherapy-Immunotherapy for Advanced Biliary Tract Cancer (BTC): A Clinical, Genomic, and Biomarker Analysis

  2025cites this paper
• Comparative Prognostic Roles of β-Catenin Expression and Tumor–Stroma Ratio in Pancreatic Cancer: Neoadjuvant Chemotherapy vs. Upfront Surgery

  2025cites this paper
• First-line treatment with chemotherapy, surufatinib (an angio-immuno kinase inhibitor), and camrelizumab (an anti-PD-1 antibody) for locally advanced or metastatic pancreatic ductal adenocarcinoma: a phase Ib/II randomized study

  2025cites this paper
• Development and validation of a CT-based radiomics model to predict survival-graded fibrosis in pancreatic ductal adenocarcinoma

  2024cites this paper
• Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer: a multicenter, randomized, phase II study

  2024influential citation
• Efficacy of nab‑paclitaxel vs. Gemcitabine in combination with S‑1 for advanced pancreatic cancer: A multicenter phase II randomized trial

  2024cites this paper
• Tumor fibrosis correlates with the survival of patients with pancreatic adenocarcinoma and is predictable using clinicoradiological features

  2022cites this paper
• Nab-paclitaxel plus tegafur gimeracil oteracil potassium capsule (S-1) as first-line treatment for advanced biliary tract adenocarcinoma: a phase 2 clinical trial

  2021cites this paper
• Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma

  2020cites this paper
• The Strain Ratio as Obtained by Endoscopic Ultrasonography Elastography Correlates With the Stroma Proportion and the Prognosis of Local Pancreatic Cancer.

  2020cites this paper
• Efficacy and toxicity comparison of nab-paclitaxel plus S-1 and nab-paclitaxel plus gemcitabine as first-line chemotherapy for metastatic pancreatic cancer

  2020cites this paper
• Patient-Derived Xenograft Models of Pancreatic Cancer: Overview and Comparison with Other Types of Models

  2020cites this paper
• Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study

  2020cites this paper
• Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma

  2020cites this paper
• Role of the tumor microenvironment in pancreatic cancer

  2019cites this paper
• Efficacy and safety comparison of nabpaclitaxel plus S-1 and gemcitabine plus S-1 as first-line chemotherapy for metastatic pancreatic cancer

  2018cites this paper
• Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase II trial

  2018cites this paper
• Pancreatic cancer models for translational research

  2017cites this paper
• Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions

  2017cites this paper
• Nab-paclitaxel plus S-1 in advanced pancreatic adenocarcinoma (NPSPAC): a single arm, single center, phase II trial

  2017cites this paper
• Pseudomonas aeruginosa-mannose-sensitive hemagglutinin inhibits pancreatic cancer cell proliferation and induces apoptosis via the EGFR pathway and caspase signaling

  2016cites this paper